Literature DB >> 9798034

The impact of candidemia on length of hospital stay, outcome, and overall cost of illness.

A M Rentz1, M T Halpern, R Bowden.   

Abstract

Although numerous studies have examined trends in nosocomial fungal infections, few have specifically addressed the cost of care associated with candidemia. This study analyzes the direct medical costs associated with treating candidemia in the United States. The study design was a cost-of-illness analysis estimating the average cost of candidemia for a single episode of care. Data were obtained from three sources: the 1993 Healthcare Cost and Utilization Project of the Agency for Health Care Policy and Research, the relevant literature, and a clinical expert in systemic fungal infections. The estimated cost (1997 U.S.$) of an episode of care for candidemia is $34,123 per Medicare patient and $44,536 per private insurance patient. The major cost associated with candidemia is that of an increased hospital stay. The estimated cost of care for candidemia may change in the future because of the use of more expensive antifungal treatments with improved safety and efficacy profiles.

Entities:  

Mesh:

Year:  1998        PMID: 9798034     DOI: 10.1086/514955

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  78 in total

Review 1.  The cost of treating systemic fungal infections.

Authors:  R van Gool
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 2.  Prophylaxis and treatment of invasive candidiasis in the intensive care setting.

Authors:  L Ostrosky-Zeichner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-10       Impact factor: 3.267

3.  Canadian clinical practice guidelines for invasive candidiasis in adults.

Authors:  Eric J Bow; Gerald Evans; Jeff Fuller; Michel Laverdière; Coleman Rotstein; Robert Rennie; Stephen D Shafran; Don Sheppard; Sylvie Carle; Peter Phillips; Donald C Vinh
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

4.  Secondary data bases and their use in outcomes research: a review of the area resource file and the Healthcare Cost and Utilization Project.

Authors:  A E Best
Journal:  J Med Syst       Date:  1999-06       Impact factor: 4.460

5.  Multilocus sequence typing for analyses of clonality of Candida albicans strains in Taiwan.

Authors:  Kuo-Wei Chen; Yee-Chun Chen; Hsiu-Jung Lo; Frank C Odds; Tzu-Hui Wang; Chi-Yang Lin; Shu-Ying Li
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

Review 6.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 7.  Epidemiology of invasive candidiasis: a persistent public health problem.

Authors:  M A Pfaller; D J Diekema
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

8.  Risk factors for fluconazole-resistant Candida glabrata bloodstream infections.

Authors:  Ingi Lee; Neil O Fishman; Theoklis E Zaoutis; Knashawn H Morales; Mark G Weiner; Marie Synnestvedt; Irving Nachamkin; Ebbing Lautenbach
Journal:  Arch Intern Med       Date:  2009-02-23

Review 9.  Surface glycans of Candida albicans and other pathogenic fungi: physiological roles, clinical uses, and experimental challenges.

Authors:  James Masuoka
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

10.  Engineered control of cell morphology in vivo reveals distinct roles for yeast and filamentous forms of Candida albicans during infection.

Authors:  Stephen P Saville; Anna L Lazzell; Carlos Monteagudo; Jose L Lopez-Ribot
Journal:  Eukaryot Cell       Date:  2003-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.